J&J Halts Talc Powder Sales in U.S. and Canada
Our valuation and moat rating aren't affected by this company's decision.
Johnson & Johnson’s (JNJ) decision to halt sales of talc-based baby powder in the United States and Canada doesn’t affect our valuation or wide moat rating. While the loss of the iconic product may slightly weigh on the company’s brand power and intangible asset moat source in the consumer division, we believe the increasing litigation surrounding the product’s potential to cause cancer had already impaired the brand. We don’t expect much brand damage to flow to other products, given that many of J&J's other brands are marketed under different labels like Neutrogena. Further, we believe the trust in the Johnson & Johnson name remains strong, based on decades of marketing support and research and development. From a valuation perspective, the lost sales are less than 0.1% of overall sales, representing a nonmeaningful contribution to cash flows for the firm.
On the litigation front, we don’t expect the sales strategy shift to affect the legal cases, which number close to 20,000. The decision to keep talc powder on the markets outside the U.S. and Canada reinforces J&J's belief in the safety of the product. The company has been successful in several cases defending its talc powder while losing some cases, and in one large trial loss, the $4 billion in damages was concerning. However, we expect the firm to vigorously defend itself against all cases and appeal those cases that are lost, likely leading to much lower damages. Overall, we continue to factor in $2 billion in legal costs associated with the talc cases based on the likely pathway that J&J will eventually settle the majority of the cases.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.